Value of genotyping and scar‐phenotyping for VT ablation procedures in patients with nonischemic left ventricular cardiomyopathies
Journal of Cardiovascular Electrophysiology · 2023
DOI: 10.1111/jce.16039 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cardiovascular Electrophysiology, 2023. Verfasst von Boldizsar Kovacs und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Cardiomyopathies, Tachycardia, Ventricular, Catheter Ablation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Variants of cardiomyopathy genes in patients with nonischemic cardiomyopathy (NICM) generate various phenotypes of cardiac scar and delayed enhancement cardiac magnetic resonance (DE‐CMR) imaging which may impact ventricular tachycardia (VT) management.
Methods
The objective was to compare the findings of cardiomyopathy genetic testing on DE‐CMR imaging and long‐term outcomes among patients with NICM undergoing VT ablation procedures. Image phenotyping and genotyping were performed in a consecutive series of patients referred for VT ablation and correlated to survival free of VT. Scar depth index (SDI) (% of scar at 0‐3 mm, 3‐5 mm and >5 mm projected on the closest endocardial surface) was determined.
Results
Forty‐three patients were included (11 women, 55 ± 14 years, ejection fraction (EF) 45 ± 16%) and were followed for 3.4 ± 2.9 years. Pathogenic variants (PV) were identified in 16 patients (37%) in the following genes: LMNA (n = 5) , TTN (n = 5) , DSP (n = 2) , AMLS1 (n = 1) , MYBPC3 (n = 1) , PLN (n = 1), and SCN5A (n = 1) . A ring‐like septal scar (RLSS) pattern was more often seen in patients with pathogenic variants (66% vs 15%, p = .001). RLSS was associated with deeper seated scars (SDI >5 mm 30.6 ± 22.6% vs 12.4 ± 16.2%, p = .005), and increased VT recurrence (HR 5.7 95% CI[1.8‐18.4], p = .003). After adjustment for age, sex, EF, and total scar burden, the presence of a PV remained independently associated with worse outcomes (HR 4.7 95% CI[1.22‐18.0], p = .02).
Conclusions
Preprocedural genotyping and scar phenotyping is beneficial to identify patients with a favorable procedural outcome. Some PVs are associated with an intramural, deeper seated scar phenotype and have an increase of VT recurrence after ablation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Radiology, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Radiology, University of Bordeaux, Bordeaux, France.
ORCID-Profile: Michael Ghannam, Jackson Liang, Hubert Cochet, Frank Bogun
Zitieren
APA
Kovacs, B., Ghannam, M., Liang, J., Moccoro, E., Attili, A., Cochet, H., Helms, A., Latchamsetty, R., Jongnarangsin, K., Morady, F., & Bogun, F. (2023). Value of genotyping and scar‐phenotyping for VT ablation procedures in patients with nonischemic left ventricular cardiomyopathies. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/jce.16039
Vancouver
Kovacs B, Ghannam M, Liang J, Moccoro E, Attili A, Cochet H, et al. Value of genotyping and scar‐phenotyping for VT ablation procedures in patients with nonischemic left ventricular cardiomyopathies. Journal of Cardiovascular Electrophysiology. 2023. doi:10.1111/jce.16039
BibTeX
@article{Kovacs2023,
author = {Kovacs, Boldizsar and Ghannam, Michael and Liang, Jackson and Moccoro, Emmeline and Attili, Anil and Cochet, Hubert and Helms, Adam and Latchamsetty, Rakesh and Jongnarangsin, Krit and Morady, Fred and Bogun, Frank},
title = {Value of genotyping and scar‐phenotyping for VT ablation procedures in patients with nonischemic left ventricular cardiomyopathies},
journal = {Journal of Cardiovascular Electrophysiology},
year = {2023},
doi = {10.1111/jce.16039}
}
EUVIMED